Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 18/20 | 0.53 |
| ▸ | AR | P10275 | 3/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13747310 | 0.83 | PGR (0.47) | PGRARNR3C1KDM4EALDH1A1 | |
| SCHEMBL4192784 | 0.79 | PGR (0.48) | PGRARNR3C1KDM4EALDH1A1 | |
| SCHEMBL4182770 | 0.75 | PGR (0.62) | PGRARNR3C1KDM4EALDH1A1 | |
| SCHEMBL5358293 | 0.68 | PGR (0.71) | PGRARNR3C1NR3C2 | |
| SCHEMBL9709027 | 0.68 | ALDH1A1 (0.48) | PGRARNR3C1KDM4EALDH1A1 | |
| SCHEMBL29677108 | 0.68 | PGR (0.70) | PGRARNR3C1KDM4EALDH1A1 | |
| SCHEMBL16812765 | 0.68 | PGR (0.70) | PGRARNR3C1KDM4EALDH1A1 | |
| SCHEMBL30973139 | 0.68 | KDM4E (0.83) | PGRARKDM4EALDH1A1MAPT | |
| SCHEMBL4186837 | 0.67 | PGR (0.67) | PGRARNR3C1KDM4EALDH1A1 | |
| SCHEMBL6648733 | 0.67 | PGR (1.00) | PGRARNR3C1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102404-A1 | THYROID STIMULATING HORMONE RECEPTOR (TSHR) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2026-04-16 | — | — | US | disclosed |
| WO-2009103007-A2 | STEROID HORMONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009103007-A2 | STEROID HORMONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102404-A1 | THYROID STIMULATING HORMONE RECEPTOR (TSHR) ANTAGONISTS AND USES THEREOF | TSHR, TRHR, THRB | PGR 252/4885AR 275/4885NR3C1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.